Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · IEX Real-Time Price · USD
0.767
+0.047 (6.53%)
Apr 23, 2024, 10:01 AM EDT - Market open
Forte Biosciences Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Forte Biosciences stock has a target of 2.75, which predicts an increase of 258.54% from the current stock price of 0.77.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for FBRX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 5 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ladenburg Thalmann | Ladenburg Thalmann | Hold → Strong Buy Upgrades $2.75 | Hold → Strong Buy | Upgrades | $2.75 | +258.54% | Apr 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Sell → Hold Upgrades n/a | Strong Sell → Hold | Upgrades | n/a | n/a | Sep 20, 2021 |
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 3, 2021 |
| Chardan Capital | Chardan Capital | Strong Buy → Strong Sell Downgrades n/a | Strong Buy → Strong Sell | Downgrades | n/a | n/a | Sep 3, 2021 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 3, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.63
from -1.00
EPS Next Year
-0.42
from -0.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 9.5M | 23.6M | 56.7M |
| Avg | n/a | n/a | 9.2M | 23.0M | 55.1M |
| Low | n/a | n/a | 8.8M | 22.1M | 52.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 157.4% | 147.1% |
| Avg | - | - | - | 150.0% | 140.0% |
| Low | - | - | - | 140.2% | 130.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.65 | -0.43 | -1.87 |
| Avg | -0.63 | -0.42 | -1.82 |
| Low | -0.61 | -0.40 | -1.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.